# EXCLAIM-2 (NCT04129502)

> TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04129502
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions: TAK-788; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 354
- Primary outcome: Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

## Indexed commentary on EXCLAIM-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- YouTube: 6
- Podcasts: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=exclaim-2-nct04129502

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04129502", "email": "<work email>"}; the inbox owner confirms by the emailed link.